Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
P-CD19CD20-ALLO1 · 1 trial · 10 indications
Rate of DLT's
| Arm | Type | Description |
|---|---|---|
| P-CD19CD20-ALLO1 CAR-T Cells (Arm S) | EXPERIMENTAL | P-CD19CD20-ALLO1 following conditioning chemotherapy regimen S. Rimiducid may be administered. |
| P-CD19CD20-ALLO1 CAR-T Cells (Arm LD 750) | EXPERIMENTAL | P-CD19CD20-ALLO1 following conditioning chemotherapy regimen LD 750. Rimiducid may be administered. |
| P-CD19CD20-ALLO1 CAR-T Cells (Arm LD 1000) | EXPERIMENTAL | P-CD19CD20-ALLO1 following conditioning chemotherapy regimen LD 1000. Rimiducid may be administered. |
| Name | Type | Description |
|---|---|---|
| P-CD19CD20-ALLO1 | BIOLOGICAL | Single weight-based IV administration |
| Rimiducid | DRUG | Single weight-based IV administration |
Inclusion Criteria 1. Must have signed written, informed consent. 2. Males or females ≥ 18 years of age. 3. Must have prior biopsy proven confirmed diagnosis of DLBCL NOS (including DLBCL arising from indolent lymphomas), HGBL, PMBCL,and tFL or follicular lymphoma Grade 3B. 4. Diagnosis of the dise...
P-CD19CD20-ALLO1 is an investigational allogeneic CAR-T cell therapy being studied for the treatment of B cell malignancies, including Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, Transformed Follicular Lymphoma, and Follicular Lymphoma Grade 3B. It is currently in Phase 1 clinical development.
P-CD19CD20-ALLO1 is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The therapy is an allogeneic CAR-T cell product being evaluated in oncology, specifically for B cell malignancies.
P-CD19CD20-ALLO1 is in Phase 1 clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety and efficacy in patients with B cell malignancies.
P-CD19CD20-ALLO1 is being studied in a Phase 1 clinical trial with the identifier NCT06014762. The trial is titled 'P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies' and is active but not recruiting participants. The study is enrolling up to 120 participants in the United States.
P-CD19CD20-ALLO1 is classified as a monoclonal antibody modality, but it is specifically an allogeneic CAR-T cell therapy. This means it involves genetically engineered T cells from a donor that are designed to target CD19 and CD20 antigens on B cells. It is being developed for the treatment of B cell malignancies.